Login to Your Account

Other News To Note

Friday, April 19, 2013
• Epizyme Inc., of Cambridge, Mass., said it signed a deal with Abbott, of Abbott Park, Ill., to develop a molecular companion diagnostic test for use with EPZ-5676, its inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription